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Objective: The aim of this study was to evaluate whether serum COMP (cartilage 
oligomeric matrix protein) can estimate the therapeutic response of rheumatoid arthritis 
(RA) after 6 months of treatment with etanercept. 
Methods: Forty-five RA patients receiving 25 mg of etanercept twice a week for 6 
months were registered in this prospective observational study. Clinical response to the 
therapy was evaluated by disease activity score (DAS) 28.  Laboratory 
variables―COMP, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), 
IgM-rheumatoid factor (IgM-RF), matrix metalloproteinase-3 (MMP-3), and anti-cyclic 
citrullinated peptide antibodies (anti-CCP Ab)―were assessed at baseline and after 6 
months of treatment.  We assessed the correlations between serum COMP and other 
variables and whether serum COMP is associated with DAS28 remission.  
Results: Serum COMP correlated with DAS28-ESR (p < 0.05, r = 0.40) at baseline.  
At 6 months of etanercept treatment, 10 patients entered remission (DAS28-ESR < 2.6) 
whereas the other 35 patients did not (DAS28-ESR > 2.6).  The decrement of serum 
COMP at 6 months was significant in the remission group (N = 10) but not in the 
non-remission group (N = 35).  On the other hand, CRP, ESR and MMP-3 decreased at 
6 months regardless of remission status.  IgM-RF titer as well as anti-CCP Ab titer did 
not differ at 6 months.  
Conclusions: Serum COMP at baseline reflects clinical disease activity of RA. Serum 
COMP is a valuable serologic marker to identify the subset of RA patients achieving 








Cartilage oligomeric matrix protein (COMP) is a member of the thrombospondin 
family and a noncollagenous extracellular matrix protein found mainly in cartilage, and 
plays an important role in maintaining the integrity of the collagen network [1, 2].  
COMP is released first into the synovial fluid and next diffused into the blood in 
varying disease conditions of cartilage damage; thus, serum COMP reflects the degree 
of articular cartilage involvement.  Since the amount of articular cartilage is greater in 
large joints than in small joints, serum COMP is supposed to be a marker of cartilage 
damage in large joints [3, 4, 5] though controversial observation remained [6].  The 
biological function of COMP is still unclear at the current time. 
 In recent years anti-tumor necrosis factor (TNF) therapy has been widely used in the 
clinical treatment of rheumatoid arthritis (RA), and preferential efficacy toward RA 
disease activity and joint destruction has been established [7, 8].  Etanercept is a 
recombinant TNF receptor-Fc fusion protein, and large-scale clinical trials of etanercept 
have identified a certain subset of patients, including those with lower disease activity at 
baseline, male sex and better physical functions at baseline, that can be predicted to 
achieve remission using etanercept [9]; however, the association of its clinical efficacy 
with serologic variables, especially in Japanese patients, remains unknown.  Although 
COMP was reported as predictive marker of cartilage damage and joint destruction, 
reports about serum COMP during anti-TNF therapy are few, and rarely found in Japan.  
  We have examined the efficacy and change of serologic variables in Japanese RA 
patients treated with 25 mg of etanercept twice a week for 6 months.  We have shown 
for the first time that serum COMP is an excellent marker of clinical disease activity in 
etanercept-treated RA patients compared with C-reactive protein (CRP), erythrocyte 
sedimentation rate (ESR), matrix metalloproteinase 3 (MMP-3) and autoantibodies.
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2. Materials and Methods 
 
Although this clinical study is based on post-marketing surveillance (PMS), it is a 
prospective consensus-based analysis, as described below. 
  Forty-five RA patients were selected to enroll in the present study from the Unit of 
Translational Medicine, Department of Immunology and Rheumatology, Graduate 
School of Biomedical Sciences, Nagasaki University and Sasebo Chuo Hospital, Center 
for Rheumatic Disease.  They gave their informed consent to the protocol that was 
approved by the Institutional Review Board of Nagasaki University and Sasebo Chuo 
Hospital. All of the patients fulfilled the 1987 criteria of the American College of 
Rheumatology (ACR) for RA [10]. In brief, 150 RA patients to date had received 
etanercept in Nagasaki University and Sasebo Chuo Hospital, among whom 45 patients 
were selected for the present study.  Inclusion criteria of the present study were 
treatment with 25 mg etanercept twice a week for 6 months; treatment with a stable 
dose of daily prednisolone less than 10 mg throughout the 6-month period; no 
intra-articular glucocorticoid injections during the 6-month period, and no change in 
concomitant use of disease-modifying anti-rheumatic drugs (DMARDs) during the 
6-month period.  The DMARDs introduced in the present study are slightly different 
from those in the United States and Europe, and are listed in Table 1.  Serum samples 
were collected and stored at -80 ºC at baseline and at 6 months until the assay. 
  Clinical response to the therapy was evaluated by disease activity score (DAS; 
DAS28-ESR; high disease activity > 5.1, moderate disease activity < 5.1 and > 3.2, low 
disease activity < 3.2, remission < 2.6).  Laboratory variables―COMP, C-reactive 
protein (CRP), erythrocyte sedimentation rate (ESR), IgM-rheumatoid factor (RF), 
matrix metalloproteinase-3 (MMP-3), and anti-cyclic citrullinated peptide antibodies 
(anti-CCP Ab)―were assessed at baseline and after 6 months of treatment.  All 
serologic analyses were performed on the stored samples using commercially available 
kits in accordance with instructions: COMP (COMP ELISAR, AnaMar Medical AB, 
Göteborg, Sweden), CRP (Eiken Chemical Co. Ltd., Tokyo, Japan), IgM-RF (Dade 
Behring, Marburg, Germany; cut-off value was 9.5 U/ml), MMP-3 (Daiichi Pure 
Chemicals, Fukuoka, Japan) and anti-CCP Ab (DIASTAT Anti-CCP, Axis-Shield, 
Dundee, UK; cut-off value was 4.5 U/ml). 
Statistical analyses: Within-group comparisons were made using Mann-Whitney’s U 
test. The changes from baseline were compared using Wilcoxon’s signed rank test. 
Correlations were assessed with Spearman’s correlation coefficient test.  The overall 
significance level for statistical analysis was 5% (two-sided).  P values less than 0.05 




Clinical characteristics of 45 patients at baseline 
Demographical and clinical characteristics of 45 patients are shown in Table 1.  
Most of the patients were established RA patients with high disease activity and 
classified as advanced stage.  Thirty-two of the 45 patients (71%) were taking 
low-dose predonisolone (mean dose; 6.64 ± 2.74mg daily) at entry.  Thirty-one 
patients (69%) were treated with DMARDs (18 methotrexate, 6 salazosulfapyridine, 3 
Cyclosporin A, 2 leflunomid, 2 mizoribine, 1 tacrolimus, 1 Bucillamine: 3 patients were 
treated with two DMARDs each).  
  Table 2 shows correlations of COMP with other variables at baseline.  Serum COMP 
levels correlated with DAS28-ESR (p < 0.05, r = 0.40), ESR (p < 0.05, r = 0.33) and 
CRP (p<0.05, r=0.33) at baseline (Table 2).  There was no association between serum 
COMP and age, disease duration at baseline.  
Decrement of COMP at 6 months was significant in the patients achieving remission at 
6 months 
Change of the variables over the 6-month treatment with etanercept in 45 patients is 
shown in Table 3.  The average value of serum COMP in 45 RA patients at baseline 
was 12.0 ± 3.4 U/l (Table 3); this value did not differ in patients with and without 
predonisolone treatment (data not shown).  Serum COMP had decreased at 6 months 
(p < 0.05, by Wilcoxon’s signed rank test).  CRP (p < 0.0001), ESR (p < 0.0001), 
MMP-3 (p <0.001), DAS28-ESR (p < 0.0001), mHAQ (p < 0.01) also decreased at 6 
months whereas the titers of anti-CCP Ab and IgM-RF did not change (Wilcoxon’s 
signed rank test).  
  Overall, DAS28-ESR at 6 months significantly improved, but was still evaluated as 
moderate disease activity (mean DAS28-ESR, 3.66 ± 1.28 as calculated in Table 3 at 6 
months); thus, we divided the 45 patients according to achievement of remission.  As 
shown in Table 4, at 6 months, 10 patients had entered remission whereas 35 patients 
had not. COMP, CRP, ESR and titer of anti-CCP Ab and IgM-RF were not statistically 
different between the 2 groups at baseline (Data not shown, by Mann-Whitney’s U test).  
The change of serologic variables was evaluated in the 2 groups. CRP, ESR and MMP-3 
were reduced in a similar fashion regardless of the achievement of remission; COMP 
was the only variable to be reduced in the remission group (N = 10) compared with 




A few reports of change in serum COMP during anti-TNF therapy have been reported 
in Europe and the United States.  In adalimumab trials, high serum COMP at baseline 
was considered to predict a poor outcome for the patients [11, 12].  In PMS data of 
etanercept treatment of 17 RA patients for 6 months, serum COMP decreased during the 
treatment [13]; however, there were no reports that showed the association of serum 
COMP value with the efficacy of etanercept treatment for RA.  
  We examined 45 RA patients treated with etanercept for 6 months.  Serologic 
variables of COMP, CRP, ESR, MMP-3, anti-CCP Ab, IgM-RF and DAS28-ESR were 
serially obtained at entry and at 6 months.  As shown in previous reports [14, 15], the 
serum COMP level at baseline correlated with clinical disease activity at baseline.  
However, this was the first observation that serum COMP decrement at 6 months 
correlates with disease status at 6 months, i.e., achievement of remission, as compared 
with other serologic variables.  Trial of Etanercept and Methotrexate with 
Radiographic Patient Outcomes (TEMPO) study predicted the variables at baseline for 
remission after 3 years.  Male sex, low disease activity, low mHAQ and combination 
with methotrexate at baseline were predictive of remission at 3 years [9].  In the 
present study, there was a predominant male sex tendency (7/10 in remission vs. 5/35 in 
non-remission, p = 0.07 by Chi-Square test) in the remission group, and DAS28-ESR (p 
= 0.003 by Mann-Whitney’s U test) as well as mHAQ (p = 0.04 by Mann-Whitney’s U 
test) at baseline were lower in the remission group than in the non-remission group.  
Combination therapy with DMARDs was also statistically high in the remission group 
compared with the non-remission group (10/10 in remission vs. 17/35 in non-remission, 
p = 0.014 by Fisher’s exact probability test).  Therefore, the characteristics of the 
remission group in the present study are comparable with those in the TEMPO trial, and 
the COMP level decrement at 6 months may reflect the outcome of patients.  
  In summary, we focused on the role of serum COMP in etanercept-treated Japanese 
RA patients.  In contrast to various demographic data with prognostic value, serum 
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Abbreviations 
anti-CCP Ab: anti-cyclic citrullinated peptide antibodies 
COMP: cartilage oligomeric matrix protein 
CRP: C-reactive protein  
DAS : disease activity score  
DMARDs: disease-modifying anti-rheumatic drugs  
ESR: erythrocyte sedimentation rate 
IgM-RF: rheumatoid factor 
MMP-3: matrix metalloproteinase 
PMS: post marketing surveillance  
RA: rheumatoid arthritis  
TNF: tumor necrosis factor  
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Table 1 
Demographic data of 45 RA patients at baseline 
Characteristics Data at baseline 
Age (years a) 
Female/male (n) 
Duration of disease (years a) 
Stage (n) 




Tender joints(n a) 
Swollen joints(n a) 
CRP (mg/dl a)  
ESR (mm/hr a) 
mHAQ a 
DAS28-ESR a 
55.9 ± 13.5  
33/12 
9.9 ± 6.9   
I, 0; II, 10; III, 9; IV, 26 
32  
31 
MTX, 18; SASP, 6; CsA, 3; LEF, 2; 
MZR, 2; TAC, 1; BUC, 1 
13.2 ± 7.6 
6.0 ± 4.6 
28.4 ± 33.4  
61.7 ± 36.1 
0.81 ± 0.67 
5.86 ± 1.35 
 
a M±SD 
MTX, methotrexate; SASP, salazosulufapyridine; CsA, cyclosporin A; LEF, leflunomide; 




Serum COMP at baseline correlates with disease activity of RA 



















Correlation of COMP with other variables at baseline was calculated as described in Patients 




Change of variables in 45 RA patients after 6-month treatment with etanercept  
 
Characteristics Baseline After 6 months P 
COMP(U/l a) 
CRP (mg/dl a)  
ESR (mm/hr a) 
MMP-3 (U/l a) 
Anti-CCP (U/ml a) 
IgM-RF(U/ml a) 
DAS28-ESR a  
mHAQ a 
12.0 ± 3.4 
28.4 ± 33.4  
61.7 ± 36.1 
253 ± 236 
163 ± 166 
279 ± 1030 
5.86 ± 1.35 
0.81 ± 0.67 
11.1 ± 3.0 
7.1 ± 12.1 
32.8 ± 29.0 
157 ± 194 
157 ± 163 
218 ± 848 
3.66 ± 1.28 










As compared with baseline, COMP, CRP, ESR, MMP-3, DAS28-ESR and mHAQ were 
decreased 




Serum COMP was selectively decreased in remission compared with other serologic variables 
 Remission group (N = 10) No remission group (N = 35) 
 Baseline After 6 months P Baseline After 6 months P 
COMP(U/l a) 
CRP (mg/l a) 
ESR (mm/hr a) 
MMP-3 (U/l a) 
IgM-RF(U/ml a) 
Anti-CCP (U/ml a) 
12.6 ± 4.5 
22.6 ± 33.2
39.3 ± 30.6
197 ± 125 
178 ± 381 
150 ± 171 
10.8 ± 3.6 
0.7 ± 0.9 
10.0 ± 11.2 
99 ± 58 
122 ± 273 







11.6 ± 3.1 
30.4±34.0 
68.7±35.5 
270 ± 259 
308±1154 
125 ± 161 
11.2 ± 2.9 
8.9 ± 13.2 
39.3 ± 29.4 
174 ± 215 
245 ± 952 








After 6 months of treatment, the 45 patients were divided into 2 groups: 10 patients who achieved remission and 35 patients who 
did not. CRP, ESR and MMP-3 were decreased in a similar fashion regardless of remission; the decrement of COMP was found 
only in the remission group.  
NS, not significant 
 
 
